April 4, 2013 — Corgenix Medical Corp. has announced that Atherotech Diagnostics Lab will carry its AspirinWorks Test for determining aspirin effect.
Corgenix AspirinWorks product will be used to assess aspirin effect as part of Atherotech Diagnostic Lab’s cardiometabolic testing products. AspirinWorks is the only U.S. FDA-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect.
“Atherotech’s access to the U.S. primary care market further strengthens the AspirinWorks product, a test that has proven its clinical utility by measuring aspirin effect, thereby enabling physicians to identify an additional influence on aspirin’s ability to aid in reducing heart attack and stroke risk,” said Douglass Simpson, Corgenix president and CEO.
The AspirinWorks Test identifies those individuals who have elevated thromboxane levels despite taking a daily aspirin dose, with studies showing up to 25 percent of individuals not seeing the expected beneficial effects of aspirin. The thromboxane metabolite 11dhTxB2 identified by AspirinWorks has been clinically validated through extensive research and numerous well-designed and well-powered clinical trials. The AspirinWorks 11dhTxB2 Test is FDA-cleared and used by thousands of physicians to test and guide treatment for hundreds of thousands of patients each year worldwide.
For more information: www.corgenix.com, www.aspirinworks.com
August 28, 2023 
